Genetic code

IMKI enhances brand heritage by creating custom Generative AI to assist in creation for the Luxury

Retrieved on: 
Tuesday, June 6, 2023

Those in the luxury are based on brands with heritage and strong DNA : Revisiting an iconic piece, creating the next trendy model with the brand's codes, testing creations before launching into production.

Key Points: 
  • Those in the luxury are based on brands with heritage and strong DNA : Revisiting an iconic piece, creating the next trendy model with the brand's codes, testing creations before launching into production.
  • These are some examples of what generative AI allows luxury businesses to do.
  • With its custom tool to assist in creation, IMKI's generative AI reveals its full power both by accelerating the creative process and by reducing production costs.
  • Founded in 2020 in Strasbourg, IMKI develops proprietary generative AI that allow its clients for Luxury and Culture to multiply their creative power while optimizing their production cost.

IMKI enhances brand heritage by creating custom Generative AI to assist in creation for the Luxury

Retrieved on: 
Tuesday, June 6, 2023

Those in the luxury are based on brands with heritage and strong DNA : Revisiting an iconic piece, creating the next trendy model with the brand's codes, testing creations before launching into production.

Key Points: 
  • Those in the luxury are based on brands with heritage and strong DNA : Revisiting an iconic piece, creating the next trendy model with the brand's codes, testing creations before launching into production.
  • These are some examples of what generative AI allows luxury businesses to do.
  • With its custom tool to assist in creation, IMKI's generative AI reveals its full power both by accelerating the creative process and by reducing production costs.
  • Founded in 2020 in Strasbourg, IMKI develops proprietary generative AI that allow its clients for Luxury and Culture to multiply their creative power while optimizing their production cost.

You shed DNA everywhere you go – trace samples in the water, sand and air are enough to identify who you are, raising ethical questions about privacy

Retrieved on: 
Monday, May 15, 2023

Because each person has a unique genetic code, DNA can be used to identify individual people.

Key Points: 
  • Because each person has a unique genetic code, DNA can be used to identify individual people.
  • Typically, medical practitioners and researchers obtain human DNA through direct sampling, such as blood tests, swabs or biopsies.
  • DNA that an organism has shed into the environment is known as environmental DNA, or eDNA.

Animals, humans and viruses in eDNA

    • Tiny hatchling sea turtles shed DNA as they crawl along the beach on their way to the ocean shortly after they are born.
    • Unlike blood or skin sampling, collecting eDNA causes no stress to the animal.
    • We recovered DNA matching the people, the animal patient and common animal viruses present at the time of collection.
    • Sequencing DNA that volunteers left in their footprints in the sand even yielded part of their sex chromosomes.

Ethical implications of collecting human eDNA

    • Human eDNA could present significant advances to research in fields as diverse as conservation, epidemiology, forensics and farming.
    • If handled correctly, human eDNA could help archaeologists track down undiscovered ancient human settlements, allow biologists to monitor cancer mutations in a given population or provide law enforcement agencies useful forensic information.
    • However, there are also myriad ethical implications relating to the inadvertent or deliberate collection and analysis of human genetic bycatch.
    • Policymakers, scientific communities and other stakeholders need to take human eDNA collection seriously and balance consent and privacy against the possible benefits of studying eDNA.

Does our gut microbiota really influence our health and life expectancy?

Retrieved on: 
Tuesday, May 2, 2023

There are several things that can disrupt the gut microbiota, including diet, alcohol consumption, antibiotics and inflammatory bowel disease.

Key Points: 
  • There are several things that can disrupt the gut microbiota, including diet, alcohol consumption, antibiotics and inflammatory bowel disease.
  • What’s more, transferring the gut microbiota from a thin mouse to a heavy mouse allows it to lose weight.
  • This short article aims to summarize and contextualize our recent research work on the gut microbiota.

The importance of a causal link

    • Some even suggest that microbiota could become a therapeutic target for the prevention or treatment of certain chronic diseases.
    • For the microbiota to become a therapeutic target of interest, it is essential to establish a causal link between the characteristics of the gut microbiota and chronic diseases.
    • A causal link suggests that modifying the microbiota would decrease the risk of developing a disease.

The power of genetic data

    • Mendelian randomization attempts to establish causal links from genetic data.
    • It is also not subject to the effect of confounding factors, since the genetic variations used are specifically associated with the characteristics of the gut microbiota.
    • We included genetic data from tens of thousands of individuals from several cohorts.
    • We hypothesised that, in the light of previously published data, a causal link would be revealed between gut dysbiosis and chronic diseases associated with aging.

Results that call for caution

    • However, these findings are consistent with the results of four recent randomized clinical trials showing that transferring gut microbiota from thin to heavyweight individuals does not lead to any weight loss or significant improvement in metabolic profile.
    • However, these results need to be contextualized.
    • Our results, along with results from clinical studies less prone to reverse causality and confounding bias, do not, however, support a significant effect of gut dysbiosis on chronic disease.
    • These results support the conclusion that the potential of the microbiota as a therapeutic target for chronic diseases is, at present, low.

Erasing or replacing errors in a patient's genetic code can treat and cure some genetic diseases

Retrieved on: 
Wednesday, April 19, 2023

In recent years, scientists have found that there are human genetic diseases that might be treatable, and perhaps even curable, through gene editing.

Key Points: 
  • In recent years, scientists have found that there are human genetic diseases that might be treatable, and perhaps even curable, through gene editing.
  • Liu and his team pioneered base editing and prime editing, two new innovative methods of gene editing that allow for precise alterations to a person’s genetic code.
  • Gene editing is a technique that makes it possible to purposefully change genes in the DNA of different organisms, including crops and animals.
  • Scientists are interested in developing and using genome editors because they are powerful tools for studying biology, treating human diseases and improving agriculture.
  • More than 50 clinical trials using gene editing to treat a variety of disorders are in progress.
  • According to the U.S. National Human Genome Research Institute, around 280 million individuals worldwide live with a rare genetic disease.
  • Most of these individuals have few to no treatment options, leaving them resigned to their genetic fate.

Cell-free Protein Expression Global Market Report 2023: Rapid Advancements in Biological Sciences Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, March 31, 2023

The global cell-free protein expression market size reached US$ 246.5 Million in 2022.

Key Points: 
  • The global cell-free protein expression market size reached US$ 246.5 Million in 2022.
  • Cell-free Protein Expression Market Trends:
    The rapid advancement in biological sciences is one of the key factors driving the market growth.
  • Cell-free protein expression is extensively used in the expansion of genetic code, assembly of viruses, and the synthesis of recombinant proteins for various biomolecular processes.
  • The publisher provides an analysis of the key trends in each sub-segment of the global cell-free protein expression market report, along with forecasts at the global, regional and country level from 2023-2028.

Pragma Bio Secures $10M From The Venture Collective, Merck Global Health Innovation Fund, Viking Global, and CJ Investments To Expand Its Proprietary Technology Platform To Discover Novel Medicines

Retrieved on: 
Thursday, March 23, 2023

The Venture Collective, led the round joined by investors Viking Global Investors, Merck Global Health Innovation Fund and CJ Investments (Korean-based strategic investor).

Key Points: 
  • The Venture Collective, led the round joined by investors Viking Global Investors, Merck Global Health Innovation Fund and CJ Investments (Korean-based strategic investor).
  • Pragma Bio is utilizing patient data to explore the synergistic bond between nature's chemistry found in the human body and the immune system with the goal of discovering novel medicines.
  • Furthermore, Pragma Bio has assembled a team of world-renowned drug hunters that have successfully generated over $30 billion in exits and commercialized medicines.
  • Pragma Bio is built upon the concept of bringing program code and genetic code to life in a pragmatic fashion.

Main Line Health researcher releases world's first complete resource on molecular structure of virus that causes COVID-19

Retrieved on: 
Thursday, February 16, 2023

WYNNEWOOD, Pa. , Feb. 16, 2023 /PRNewswire/ -- A biomedical researcher at the Lankenau Institute for Medical Research (LIMR), part of Main Line Health, has created a groundbreaking resource for scientists seeking to develop new and better vaccines in the fight against COVID-19.

Key Points: 
  • We will continue to need new vaccines and therapies that are safe and more effective than those available today."
  • But all the vaccines created targeted the viral spike protein, the part of the virus that binds to human cells.
  • "Dr. Thomas's efforts to scour the literature and create this open-source compilation of the SARS-CoV-2 molecular structure is an excellent contribution to the scientific community.
  • The set has reached 120,000 downloads since its January 2022 publication in Springer's Methods in Molecular Biology series.

New AI Tool Makes Speedy Gene-Editing Possible

Retrieved on: 
Thursday, January 26, 2023

Other conditions are caused, not by a mistake in the code itself, but by problems in how the cellular machinery reads DNA (epigenetics).

Key Points: 
  • Other conditions are caused, not by a mistake in the code itself, but by problems in how the cellular machinery reads DNA (epigenetics).
  • Similarly, zinc fingers can also hook onto transcription factors and pull them toward a gene segment in need of regulation.
  • The study authors' new technology, called ZFDesign, overcomes this obstacle by using artificial intelligence (AI) to model and design these interactions.
  • The model is based on data generated by the screen of nearly 50 billion possible zinc finger-DNA interactions in the researchers' labs.

NanoMosaic To Develop Novel Capture Methodologies as Dr. Abhishek Chatterjee Joins NanoMosaic Scientific Advisory Board

Retrieved on: 
Tuesday, January 24, 2023

Abhishek Chatterjee, Ph.D. joins NanoMosaic SAB.

Key Points: 
  • Abhishek Chatterjee, Ph.D. joins NanoMosaic SAB.
  • Dr. Chatterjee has developed various novel genetic code expansion tools to allow site-specific incorporation of enabling noncanonical amino acids into proteins in vivo.
  • Dr. Chatterjee is also co-founder, senior advisor and Chair of Scientific Advisory Board of BrickBio Inc.
    "NanoMosaic's powerful MosaicNeedle™ technology has the potential to revolutionize the world of protein detection and quantification.
  • The novel antibody has been designed to have higher affinities and enhanced performance on NanoMosaic Tessie™ platform.